Kodiak Sciences Inc. (KOD) stock
KODNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$97.90+0.09 (+0.09%)
Close on Nov 19, 2026Market cap $6.15BP/E –Yield –
Kodiak Sciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Kodiak Sciences's free cash flow for the twelve months ending Jun 30, 2026 was -$159.90M. For fiscal 2025 it was -$136.51M. The highest annual figure on record is -$16.82M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$136.51M | – |
| FY2024 | Dec 31, 2024 | -$117.69M | – |
| FY2023 | Dec 31, 2023 | -$195.53M | – |
| FY2022 | Dec 31, 2022 | -$243.48M | – |
| FY2021 | Dec 31, 2021 | -$199.30M | – |
| FY2020 | Dec 31, 2020 | -$87.24M | – |
| FY2019 | Dec 31, 2019 | -$39.58M | – |
| FY2018 | Dec 31, 2018 | -$29.11M | – |
| FY2017 | Dec 31, 2017 | -$17.86M | – |
| FY2016 | Dec 31, 2016 | -$16.82M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$46.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$40.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$39.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.19M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.34M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$39.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$59.72M | – |
| Q3 FY2023 | Sep 30, 2023 | -$32.99M | – |
| Q2 FY2023 | Jun 30, 2023 | -$43.43M | – |
| Q1 FY2023 | Mar 31, 2023 | -$59.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -$58.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$61.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$63.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$60.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$67.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -$56.78M | – |
| Q2 FY2021 | Jun 30, 2021 | -$39.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$35.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.98M | – |
| Q3 FY2020 | Sep 30, 2020 | -$26.18M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.97M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.11M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.85M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.07M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.21M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.00M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.49M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.26M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.95M | – |
See a number that looks wrong?